Find Reports

Select Report Type

Reimbursement Review

Displaying 1426 - 1430 of 1430

Please scroll or swipe to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Status	Submission Date	Project Number
garadacimab	TBC	garadacimab	Patient and Clinician Group input	Hereditary angioedema (HAE)	Active	Jul 31, 2024	SR0860-000
omaveloxolone	Skyclarys	omaveloxolone	Draft Recommendation Patient and Clinician Group input	Friedreich’s ataxia	Active	Oct 2, 2024	SR0864-000
Diffuse large B cell lymphoma ...			Proposed Scope	Diffuse large B	Active		PH0078-000
Multiple myeloma			Scoping Document Proposed Project Scope for PH0060-000	Multiple myeloma	Active		PH0074-000
dabrafenib trametinib	TBC	dabrafenib trametinib	Draft Recommendation and Reasons Draft Responses to the Questions from the Drug Programs Clinical & Pharmacoeconomic Combined Report Patient, Clinician and Industry Input Combined Report Supplemental Material Proposed Scope	Pediatric low grade glioma (ped LGG)	Active	Oct 7, 2024	PX0375-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 602 of 602

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1 - 25 of 25

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1426 - 1450 of 2142

Please scroll or swipe to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Bevacizumab (TBD) mCRC NSCLC Biosimilar – Details		Jun 17, 2019	Reimbursement Review		Cancelled	PC0178-000
pegaspargase		Jun 17, 2019	Reimbursement Review		Not filed	NS0002-000
ibritumomab tiuxetan		Jun 17, 2019	Reimbursement Review		Not filed	NS0003-000
Venclexta in combo Rituximab for Chronic Lymphocytic Leukemia – Details	Provincial Funding Summary Venetoclax (Venclexta) in combo Rituximab CLL – pERC Final Recommendation Venetoclax (Venclexta) in combo Rituximab CLL – Final Economic Guidance Report Venetoclax (Venclexta) in combo Rituximab CLL – Final Clinical Guidance Report Venetoclax (Venclexta) in combo Rituximab CLL - pERC Initial Recommendation Venetoclax (Venclexta) in combo Rituximab CLL – PAG Feedback on Initial Recommendation Venetoclax (Venclexta) in combo Rituximab CLL – Manufacturer Feedback on Initial Recommendation Venetoclax (Venclexta) in combo Rituximab CLL – Patient Advocacy Group Feedback on Initial Recommendation Venetoclax (Venclexta) in combo Rituximab CLL – Clinician Feedback on Initial Recommendation Venetoclax (Venclexta) in combo Rituximab CLL – Patient Advocacy Group COI Declarations Venetoclax (Venclexta) in combo Rituximab CLL – Clinician COI Declarations	Jun 17, 2019	Reimbursement Review		Complete	PC0162-000
Vizimpro for Non-Small Cell Lung Cancer – Details	Provincial Funding Summary Dacomitinib (Vizimpro) NSCLC – pERC Final Recommendation Dacomitinib (Vizimpro) NSCLC – Final Economic Guidance Report Dacomitinib (Vizimpro) NSCLC – Final Clinical Guidance Report Dacomitinib (Vizimpro) NSCLC - pERC Initial Recommendation Dacomitinib (Vizimpro) NSCLC – PAG Feedback on Initial Recommendation Dacomitinib (Vizimpro) NSCLC – Manufacturer Feedback on Initial Recommendation Dacomitinib (Vizimpro) NSCLC – Clinician Feedback on Initial Recommendation Dacomitinib (Vizimpro) NSCLC – Patient Advocacy Group COI Declarations Dacomitinib (Vizimpro) NSCLC – Clinician COI Declarations	Jun 17, 2019	Reimbursement Review		Complete	PC0129-000
doravirine lamuvidine tenofovir disoproxil fumarate	Recommendations and Reasons SR0581 Delstrigo - Patient Input for Posting.pdf New Combination Product	Jun 14, 2019	Reimbursement Review		Complete	SR0581-000
isavuconazole	Recommendations and Reasons Clinical Report Pharmacoeconomic Report	Jun 13, 2019	Reimbursement Review		Complete	SR0586-000
Trastuzumab for Breast and Gastric Cancer Biosimilar – Details		Jun 7, 2019	Reimbursement Review		Cancelled	PC0160-000
Rituximab (Truxima) for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar - Details		Jun 7, 2019	Reimbursement Review		Cancelled	PC0184-000
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details	Provincial Funding Summary Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – pERC Final Recommendation Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Final Economic Guidance Report Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Final Clinical Guidance Report Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – pERC Initial Recommendation Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – PAG Feedback on Initial Recommendation Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Manufacturer Feedback on Initial Recommendation Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Patient Advocacy Group Feedback on Initial Recommendation Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Clinician Feedback on Initial Recommendation Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Patient Advocacy Group COI Declarations Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Clinician COI Declarations	Jun 7, 2019	Reimbursement Review		Complete	PC0151-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease	Appropriate Pharmacotherapy for Inflammatory Bowel Disease	Jun 6, 2019	Health Technology Review	Technology Review	Completed	HO0003-000 - HE0018-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease		Jun 5, 2019	Health Technology Review	Technology Review	Completed	HO0003-000 - HE0018-000
Criteria for conducting Environmental Assessments in CADTH HTAs		Jun 5, 2019	Health Technology Review		In Progress	MG0017-000
Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details		May 31, 2019	Reimbursement Review		Withdrawn	PC0169-000
decitabine		May 29, 2019	Reimbursement Review		Not filed	NS0001-000
CADTH Pharmaceutical Reviews Update — Issue 8		May 23, 2019	Reimbursement Review	Pharmaceutical Review Update
Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Details	Provincial Funding Summary Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – pERC Final Recommendation Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Final Economic Guidance Report Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Final Clinical Guidance Report Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – pERC Initial Recommendation Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – PAG Feedback on Initial Recommendation Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Manufacturer Feedback on Initial Recommendation Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Clinician Feedback on Initial Recommendation Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Patient Advocacy Group COI Declarations Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Clinician COI Declarations	May 21, 2019	Reimbursement Review		Complete	PC0152-000
Imfinzi for Non-Small Cell Lung Cancer – Details	Provincial Funding Summary Imfinzi for Non-Small Cell Lung Cancer – pERC Final Recommendation Imfinzi for Non-Small Cell Lung Cancer – Final Economic Guidance Report Imfinzi for Non-Small Cell Lung Cancer – Final Clinical Guidance Report Imfinzi for Non-Small Cell Lung Cancer – pERC Initial Recommendation Imfinzi for Non-Small Cell Lung Cancer – PAG Feedback on Initial Recommendation Imfinzi for Non-Small Cell Lung Cancer – Manufacturer Feedback on Initial Recommendation Imfinzi for Non-Small Cell Lung Cancer – Clinician Feedback on Initial Recommendation Imfinzi for Non-Small Cell Lung Cancer – Patient Advocacy Group COI Declarations Imfinzi for Non-Small Cell Lung Cancer – Clinician COI Declarations	May 21, 2019	Reimbursement Review		Complete	PC0131-000
Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details	Provincial Funding Summary Palbociclib (Ibrance) Fulvestrant MBC – pERC Final Recommendation Palbociclib (Ibrance) Fulvestrant MBC – Final Economic Guidance Report Palbociclib (Ibrance) Fulvestrant MBC – Final Clinical Guidance Report Palbociclib (Ibrance) Fulvestrant MBC - pERC Initial Recommendation Palbociclib (Ibrance) Fulvestrant MBC – PAG Feedback on Initial Recommendation Palbociclib (Ibrance) Fulvestrant MBC – Manufacturer Feedback on Initial Recommendation Palbociclib (Ibrance) Fulvestrant MBC – Clinician Feedback on Initial Recommendation Palbociclib (Ibrance) Fulvestrant MBC – Patient Advocacy Group COI Declarations Palbociclib (Ibrance) Fulvestrant MBC – Clinician COI Declarations	May 21, 2019	Reimbursement Review		Complete	PC0150-000
filgrastim		May 17, 2019	Reimbursement Review		Cancelled	SE0585-000
Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	May 9, 2019	Health Technology Review	Summary with Critical Appraisal	Completed	RC1111-000
cysteamine bitartrate	Recommendation and Reasons Clinical Report Pharmacoeconomic Report Patient Group Input Submissions Implementation Advice	May 8, 2019	Reimbursement Review		Complete	SR0526-000
Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	May 3, 2019	Health Technology Review	Rapid Review	Completed	RC1104-000
Zytiga for Prostate Cancer – Details		May 3, 2019	Reimbursement Review		Withdrawn	PC0166-000
Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Apr 30, 2019	Health Technology Review	Rapid Review	Completed	RC1097-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81